Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients

International Journal of Clinical Oncology

Volumn 14, Issue 6, 2009, Pages 497-501

  Isobe, Kazutoshi ^a   Hata, Yoshinobu ^a   Takai, Yujiro ^a   Shibuya, Kazutoshi ^a   Takagi, Keigo ^a   Homma, Sakae ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Carcinoembryonic antigen; Lung cancer; Positron emission tomography; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; DRUG UPTAKE; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RADIOPHARMACEUTICALS;

EID: 72949096631     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-009-0905-4     Document Type: Article

References (17)

1. E.F. Patz Jr V.J. Lowe J.M. Hoffman, et al. 1994 Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2deoxy-D-glucose Radiology 191 379 382 8153309
2. F.G. Duhaylongsod V.J. Lowe E.F. Patz, et al. 1995 Detection of primary and recurrent lung cancer by means of F-18 positron emission tomography (FDG-PET) J Thorac Cardiovasc Surg 110 130 139 10.1016/S0022-5223(05)80018-2 1:STN:280:DyaK2Mzjtlyisg%3D%3D 7609536
3. A. Frank D. Lefkowitz S. Jaeger, et al. 1995 Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings Int J Radiat Oncol Biol Phys 32 1495 1512 1:STN:280:DyaK2Mzmt1Kiug%3D%3D 7635795
4. T. Inoue E.E. Kim R. Komaki, et al. 1995 Detecting recurrent or residual lung cancer with FDG-PET J Nucl Med 36 788 793 1:STN:280:DyaK2M3ls12ksw%3D%3D 7738649
5. D. Ukena D. Hellwig I. Palm, et al. 2000 Value of positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma Pneumologie 54 49 53 10.1055/s-2000-9063 1:STN:280:DC%2BD3c7ps1ejtw%3D%3D 10731756 (Pubitemid 30133025)
6. R.J. Hicks V. Kalff M.P. Macmanus, et al. 2001 The utility of 18F-FDG PET for suspected lung cancer recurrence: diagnostic value and impact on patient management J Nucl Med 42 1605 1613 1:STN:280:DC%2BD3MnksValtg%3D%3D 11696628
7. D. Hellwig A. Groschel T.P. Graeter, et al. 2006 Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence treated non-small cell lung cancer Eur J Nucl Med Mol Imaging 33 13 21 10.1007/s00259-005-1919-4 16151765 (Pubitemid 41785304)
8. J. Rubins M. Unger G.L. Colice 2007 Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition) Chest 132 355 367 10.1378/chest.07- 1390
9. J.F. Bruzzi R.F. Munden J.F. Bruzzi, et al. 2006 PET/CT imaging of lung cancer J Thorac Imaging 21 123 136 10.1097/00005382-200605000-00004 16770229
10. F.L. Flanagan F. Dehdashti O.A. Ogunbiyi, et al. 1998 Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann Surg 227 319 323 10.1097/00000658-199803000-00001 1:STN:280:DyaK1c7os1arsw%3D%3D 9527052 (Pubitemid 28131010)
11. P. Flamen O.S. Hoekstra F. Homans, et al. 2001 Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) Eur J Cancer 37 862 869 10.1016/S0959-8049(01)00049-1 1:CAS:528:DC%2BD3MXislGhtbw%3D 11313174 (Pubitemid 32323964)
12. G.F. Buccheri B. Violante A.M. Sartoris, et al. 1986 Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma Cancer 57 2389 2396 10.1002/1097-0142(19860615)57:12<2389::AID-CNCR2820571225>3.0.CO;2-# 1:STN:280:DyaL287ovFCmtw%3D%3D 3697937
13. N. Sawabata M. Ohta S. Takeda 2002 Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer Ann Thorac Surg 74 174 179 10.1016/S0003-4975(02)03662-7 12118753 (Pubitemid 34734668)
14. G. Buccheri D. Ferrigno 2003 Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test Ann Thorac Surg 75 973 980 10.1016/S0003-4975(02)04638-6 12645726 (Pubitemid 36298378)
15. M. Okada W. Nishio T. Sakamoto, et al. 2004 Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1000 consecutive resections for clinical stage I disease Ann Thorac Surg 78 216 221 10.1016/j.athoracsur.2004.02.009 15223432 (Pubitemid 38833935)
16. Y. Sakao S. Tomimitsu Y. Takeda, et al. 2004 Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma Eur J Cardiothorac Surg 25 520 522 10.1016/j.ejcts.2004.01.029 15037265 (Pubitemid 38376063)
17. I.H. Shon M.J. O'Doherty M.N. Maisey 2002 Positron emission tomography in lung cancer Semin Nucl Med 32 240 271 10.1053/snuc.2002.126059 12524650 (Pubitemid 35332972)